Maxigen Biotech Inc.

TWSE:1783 Stock Report

Market Cap: NT$4.2b

Maxigen Biotech Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Ching-Ting Chen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure3.3yrs
CEO ownership0.1%
Management average tenureno data
Board average tenure3.4yrs

Recent management updates

Recent updates

Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft Earnings

Nov 20
Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft Earnings

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Apr 22
Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Apr 01
We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 16
Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Feb 23
The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Feb 02
Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Jan 10
Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Dec 14
Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Nov 22
If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

CEO Compensation Analysis

How has Ching-Ting Chen's remuneration changed compared to Maxigen Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

NT$155m

Jun 30 2024n/an/a

NT$147m

Mar 31 2024n/an/a

NT$150m

Dec 31 2023n/an/a

NT$166m

Sep 30 2023n/an/a

NT$191m

Jun 30 2023n/an/a

NT$192m

Mar 31 2023n/an/a

NT$163m

Dec 31 2022n/an/a

NT$139m

Sep 30 2022n/an/a

NT$110m

Jun 30 2022n/an/a

NT$99m

Mar 31 2022n/an/a

NT$87m

Dec 31 2021NT$1mNT$540k

NT$88m

Compensation vs Market: Insufficient data to establish whether Ching-Ting's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Insufficient data to compare Ching-Ting's compensation with company performance.

CEO

Ching-Ting Chen

3.3yrs

Tenure

NT$1,322,000

Compensation

Ms. Ching-Ting Chen is Institutional Director of TCI Co. Ltd. from June 25, 2024 and serves as Head of Research & Design Center since February 5, 2020. She is General manager of TCI CO., Ltd.She has been...

Board Members

NamePositionTenureCompensationOwnership
Ching-Ting Chen
GM & Representative Director3.1yrsNT$1.32m0.11%
NT$ 4.7m
Yung-Hsiang Lin
Chairman of the Board3.4yrsno datano data
Tsiu-Yuan Li
Representative Director9.5yrsno datano data
Chen-Chen Fu
Representative Director3.4yrsno datano data
Song Yuan Liao
Independent Director3.4yrsno datano data
Zeng Zhong Ming
Independent Director3.4yrsno datano data
Tsong-Jieh Chiou
Directorno datano datano data
Shih-Ming Lai
Directorno datano datano data

3.4yrs

Average Tenure

Experienced Board: 1783's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:40
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Maxigen Biotech Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Regina LeeCapital Securities Corporation
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.
Hsiu Chi LinMasterlink Securities Corp.